参芪扶正注射液联合化学药物治疗进展期胃癌的Meta分析

Meta-Analysis of Shenqifuzheng Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer

目的：比较参芪扶正注射液联合化学药物与单纯化疗治疗进展期胃癌的疗效和安全性。方法：用计算机检索1999~2012年中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、万方数据库、Pubmed、Medline、Embase database和Cochrane Library收录的相关资料,收集参芪扶正联合化疗治疗胃癌的随机对照试验（RCT）,应用RevMan 5.1软件的Meta分析来评估这些治疗的效果。结果：共纳入17篇文献（1214例进展期胃癌患者）。Meta分析结果显示,与单纯化疗相比,参芪扶正联合化疗可以提高临床受益率（clinical benefit rate,CBR）,比值比（odds ratio,OR）=1.99,95%可信区间（95%confidence interval,CI）∶1.24-3.17,P〈0.004;改善生存质量评分（KPS评分）,OR=3.65,95%CI∶2.57-5.18,P〈0.00001;增强免疫功能及减少白细胞（OR=0.48,95%CI∶0.23-0.97,P=0.04）;且不增加恶心、呕吐、肝功能损害及脱发等不良反应发生率。结论：与单纯化疗相比,参芪扶正联合化疗可提高进展期胃癌治疗的CBR,提高患者的生存质量,增强患者的免疫功能,且并不增加不良反应发生率。

Objective：To compare the efficacy and safety of Shenqifuzheng combined with chemotherapy and chemotherapy alone in the treatment of advavced gastric cancer.Methods：Data about randomized controlled trials（RCTs）of Shenqifuzheng combined with chemotherapy for gastric cancer was retrieved from Chinese Biomedical Literature Database（CBM）,China National Knowledge Infrastructure（CNKI）,Wanfang database,PubMed,Medline,Embase database,and Cochrane Library from 1999 to 2012.Meta-analysis was done to evaluate the results of these studies by RevMan 5.1 software.Results：A total of 17 literatures（1214 cases）were selected for the Meta analysis.The analysis suggested that compared to the chemotherapy alone,the combination of chemotherapy with shenqifuzheng had a statistically significant benefit in CBR（clinical benefit rate）[odds ratio（OR）=1.99,95%confidence interval,（95% CI）：1.24-3.17,P0.004],KPS（OR=3.65,95%CI：2.57-5.18,P 0.00001）,and it could improve immune function and decrease leukopenia（OR=0.48,95%CI：0.23-0.97,P=0.04）.The incidences of untoward redctions such as nausea,vomiting,liver function damage and alopecia.Conclusions：Compared to the chemotherapy alone,shenqifuzheng combined with chemotherapy can improve CBR and life quality in the treatment for gastric cancer,improve immune function and decrease incidences of unfoward reactions.